Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Strong-Buy at Lucid Cap Mkts

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities researchers at Lucid Cap Mkts to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

Other equities analysts have also recently issued research reports about the company. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 8th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Price Performance

Shares of NASDAQ:TVRD opened at $1.94 on Tuesday. The company’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $2.94. The stock has a market capitalization of $25.88 million, a price-to-earnings ratio of -0.70 and a beta of 0.32. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts anticipate that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds have recently made changes to their positions in TVRD. GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics during the second quarter worth about $34,000. Arax Advisory Partners increased its stake in shares of Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the period. JPMorgan Chase & Co. bought a new position in Tvardi Therapeutics in the 2nd quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics in the 2nd quarter valued at approximately $43,000. Finally, HRT Financial LP acquired a new stake in Tvardi Therapeutics during the 4th quarter worth approximately $47,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.